A Randomized, Double-Blind, Placebo-Controlled 12-Week Study to Determine the Efficacy of EPA+DHA (SC401B) on Hypertriglyceridemia (TG ≥ 500 mg/dL and ≤ 2000 mg/dL)

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled 12-Week Study to Determine the Efficacy of EPA+DHA (SC401B) on Hypertriglyceridemia (TG ≥ 500 mg/dL and ≤ 2000 mg/dL)

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 28 Nov 2016

At a glance

  • Drugs Eicosapentaenoic acid/docosahexaenoic acid (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Therapeutic Use
  • Sponsors Sancilio & Company
  • Most Recent Events

    • 22 Nov 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as study never initiated. IND placed on Hold
    • 14 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top